Purine News and Research

RSS
BCX4945 proves effective at clearing malaria infections

BCX4945 proves effective at clearing malaria infections

PNP reaches several major objectives in cancer therapeutic product development

PNP reaches several major objectives in cancer therapeutic product development

Research provides new clues for compulsive behavior, cognitive defects linked with LND

Research provides new clues for compulsive behavior, cognitive defects linked with LND

Pharmasset reports positive data from PSI-7977 and PSI-938 HCV clinical programs

Pharmasset reports positive data from PSI-7977 and PSI-938 HCV clinical programs

BioCryst reports Phase 2 trial data of forodesine in patients with CLL

BioCryst reports Phase 2 trial data of forodesine in patients with CLL

Pharmasset commences combination study of PSI-7977 and PSI-938 nucleotide analogs in HCV

Pharmasset commences combination study of PSI-7977 and PSI-938 nucleotide analogs in HCV

Sugar-sweetened drinks can increase gout risk in women

Sugar-sweetened drinks can increase gout risk in women

BioCryst to present data on BCX4208 for gout at ACR Scientific Meeting

BioCryst to present data on BCX4208 for gout at ACR Scientific Meeting

Caffeine intake increases risk for recurrent gout attacks

Caffeine intake increases risk for recurrent gout attacks

Pharmasset's PSI-938 phase I monotherapy trial shows positive result for HCV treatment

Pharmasset's PSI-938 phase I monotherapy trial shows positive result for HCV treatment

BioCryst reports results from forodesine studies for CTCL and CLL

BioCryst reports results from forodesine studies for CTCL and CLL

Mechanism linking brain activity to sleep discovered

Mechanism linking brain activity to sleep discovered

Investment report on BioCryst Pharmaceuticals

Investment report on BioCryst Pharmaceuticals

Positive results from interim analysis of ongoing Phase 2a study of BCX4208

Positive results from interim analysis of ongoing Phase 2a study of BCX4208

DARA Therapeutics collaborates to advance clinical study of KRN5500 for CIPN in cancer patients

DARA Therapeutics collaborates to advance clinical study of KRN5500 for CIPN in cancer patients

Phase 1 SAD study of PSI-938 for HCV initiated

Phase 1 SAD study of PSI-938 for HCV initiated

Slavica BioChem scientists reverse multidrug resistance in lung cancer using small molecules

Slavica BioChem scientists reverse multidrug resistance in lung cancer using small molecules

PSI-879 nominated as second development candidate for treating HCV infection

PSI-879 nominated as second development candidate for treating HCV infection

Research shows how p53 mutations link to high-grade breast cancer, poor outcomes

Research shows how p53 mutations link to high-grade breast cancer, poor outcomes